Novel association between CD74 polymorphisms and hematologic toxicity in patients with nsclc after platinum-based chemotherapy

Clinical Lung Cancer

Volumn 15, Issue 1, 2014, Pages

  Tan, Xiaoming ^a   Wu, Qihan ^b   Cai, Yanyan ^b   Zhao, Xueying ^c   Wang, Shingming ^c   Gao, Zhiqiang ^d   Yang, Yang ^e   Li, Xiaoying ^c   Qian, Ji ^c   Wang, Jiucun ^c   Su, Bo ^e   Chen, Hongyan ^c   Han, Baohui ^d   Jiang, Gening ^e   Lu, Daru ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e TONGJI UNIVERSITY   (China)

Author keywords

CD74; Hematologic toxicity; NSCLC; Platinum based chemotherapy; Polymorphism

Indexed keywords

CD74 ANTIGEN; DOCETAXEL; GEMCITABINE; MIGRATION INHIBITION FACTOR; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; WILD TYPE;

CD74; HEMATOLOGIC TOXICITY; NSCLC; PLATINUM-BASED CHEMOTHERAPY; POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GENOTYPE; HAPLOTYPES; HEMATOLOGIC DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891835059     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.08.006     Document Type: Article

References (35)

1. J. Ferlay, H.R. Shin, and F. Bray et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. D.M. Parkin, F. Bray, and J. Ferlay et al. Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. D.M. Parkin, P. Pisani, and J. Ferlay Estimates of the worldwide incidence of 25 major cancers in 1990 Int J Cancer 80 1999 827 841
4. K. Osawa, C. Nakarai, and K. Uchino et al. XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients Int J Mol Sci 13 2012 16658 16667
5. C.A. Rabik, and M.E. Dolan Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 33 2007 9 23
6. J.H. Schiller, D. Harrington, and C.P. Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
7. E.A. Chrischilles, J.F. Pendergast, and K.L. Kahn et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer J Clin Oncol 28 2010 620 627
8. L. Sreeja, V.S. Syamala, and V. Syamala et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India J Cancer Res Clin Oncol 134 2008 645 652
9. P.L. Vera, and K.L. Meyer-Siegler Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis BMC Res Notes 4 2011 395
10. A. Nemajerova, P. Mena, and G. Fingerle-Rowson et al. Impaired DNA damage checkpoint response in MIF-deficient mice EMBO J 26 2007 987 997
11. A. Nemajerova, U.M. Moll, and O. Petrenko et al. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle Cell Cycle 6 2007 1030 1034
12. M. Cummings, T. Siitonen, and K. Higginbottom et al. p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis Br J Haematol 116 2002 421 428
13. J. Bartek, and J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 3 2003 421 429
14. W. Wu, W. Zhang, and R. Qiao et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population Clin Cancer Res 15 2009 3889 3895
15. H. Conroy, L. Mawhinney, and S.C. Donnelly Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link QJM 103 2010 831 836
16. L. Leng, C.N. Metz, and Y. Fang et al. MIF signal transduction initiated by binding to CD74 J Exp Med 197 2003 1467 1476
17. G.X. Ding, S.Q. Zhou, and Z. Xu et al. The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese J Surg Oncol 100 2009 106 110
18. S. Wu, J. Lian, and H. Tao et al. Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis Oncol Lett 2 2011 1261 1267
19. Q. Yuan, M. Wang, and M. Wang et al. Macrophage migration inhibitory factor gene -173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis Mol Biol Rep 39 2012 3109 3115
20. R.P. Donn, E. Shelley, and W.E. Ollier et al. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis Arthritis Rheum 44 2001 1782 1785
21. T. Yuan, C. Tang, and M. Chen et al. Influence of human MIF promoter polymorphism on hepatocellular carcinoma prognosis Genet Mol Res 2013 12(AOP). [Epub ahead of print]
22. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. D.P. Carbone, and J.D. Minna Chemotherapy for non-small cell lung cancer BMJ 311 1995 889 890
24. T. Calandra, and T. Roger Macrophage migration inhibitory factor: a regulator of innate immunity Nat Rev Immunol 3 2003 791 800
25. E.J. Pawlak-Byczkowska, and H.J. Hansen et al. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma Cancer Res 49 1989 4568 4577
26. M. McClelland, L. Zhao, and S. Carskadon et al. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer Am J Pathol 2 2009 638 646
27. I. Shachar, and M. Haran The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival Leuk Lymphoma 52 2011 1446 1454
28. F. Borghese, and F.I. Clanchy CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease Expert Opin Ther Targets 15 2011 237 251
29. J.M. Pellikainen, and V.M. Kosma Activator protein-2 in carcinogenesis with a special reference to breast cancer - a mini review Int J Cancer 120 2007 2061 2067
30. L. Zhang, L. Jia, and S. Cui et al. AP-2α-dependent regulation of Bcl-2/Bax expression affects apoptosis in the trophoblast J Mol Histol 43 2012 681 689
31. K.W. Cheng, C.K. Cheng, and P.C. Leung Differential role of PR-A and -B isoforms in transcription regulation of human GnRH receptor gene Mol Endocrinol 15 2001 2078 2092
32. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
33. M.J. Tsai, and B.W. O'Malley Molecular mechanisms of action of steroid/thyroid receptor superfamily members Annu Rev Biochem 63 1994 451 486
34. C. Sacristán, S.A. Schattgen, and L.J. Berg et al. Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells Eur J Immunol 39 2009 2584 2595
35. S. Gu, Q. Wu, and X. Zhao et al. Association of Casp3 polymorphism with hematologic toxicity in advanced NSCLC patients treated with platinum-based chemotherapy Cancer Sci 103 2012 1451 1459